- July 8 - 9, 2018
July 9-10, 2018
Hyatt Regency Bethesda
The FDA and PVRI have expressed a willingness to leverage their combined strengths for the joint development of this annual meeting to facilitate FDA’s engagement with scientists from academia, government, and industry on regulatory science questions that impact drug development and safety prediction for orphan pulmonary vascular diseases.
Goals and Objectives
- To provide a forum for open discussion among scientists from academia, government, the pharmaceutical industry, and other stakeholders on pulmonary vascular diseases and the novel therapies being developed to treat them.
- To accelerate the development of these therapies by discussing the safety and efficacy data and the level of data needed to support their approval.
Who Should Attend:
This annual meeting is intended for scientists from academia, government, and industry responsible for developing and regulating products for the treatment of pulmonary hypertension as well as those parties responsibly for the treatment of these patients.
The primary audience includes leading academic experts, interested pharmaceutical companies, regulatory agencies, patient advocacy groups, non-profit organizations, scientists, patient representatives, and healthcare providers who work in this therapeutic area.
Meg Pease-Fye – firstname.lastname@example.org